Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (43 quarters reported)
$328M in Q4 2015 → $20.9M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Cue Biopharma Inc | 8.0% | New | 52,928 | $1.67M |
| PP Praxis Precision Medicines I | 7.1% | Unchanged | 4,450 | $1.49M |
| Moonlake Immunotherapeutics | 6.3% | Unchanged | 67,500 | $1.31M |
| Fennec Pharmaceuticals Inc | 5.8% | Unchanged | 112,434 | $1.21M |
| Royalty Pharma PLC | 5.7% | Unchanged | 21,400 | $1.2M |
| Compass Pathways PLC | 5.4% | Unchanged | 80,000 | $1.13M |
| MP Milestone Pharmaceuticals In | 5.3% | Unchanged | 820,000 | $1.1M |
| Benitec Biopharma Inc | 4.0% | Unchanged | 62,000 | $830K |
| Syndax Pharmaceuticals Inc | 3.8% | Unchanged | 36,000 | $787K |
| Biohaven Ltd | 3.7% | Unchanged | 51,700 | $769K |
| Geron Corp | 3.5% | Unchanged | 578,000 | $740K |
| UN Uniqure Nv | 3.2% | Unchanged | 14,700 | $677K |
| Ardelyx Inc | 3.1% | Unchanged | 128,650 | $656K |
| LH Lantheus Hldgs Inc | 2.9% | Unchanged | 5,500 | $610K |
| Disc Medicine Inc | 2.8% | Unchanged | 8,100 | $592K |
| Sarepta Therapeutics Inc | 2.4% | Unchanged | 28,500 | $512K |
| Humacyte Inc | 2.4% | Unchanged | 650,000 | $507K |
| Kura Oncology Inc | 2.4% | Unchanged | 46,000 | $505K |
| Viatris Inc | 2.1% | Unchanged | 27,700 | $440K |
| Dyne Therapeutics Inc | 1.9% | Unchanged | 18,000 | $400K |
| Bridgebio Pharma Inc | 1.8% | Unchanged | 5,000 | $372K |
| Edgewise Therapeutics Inc | 1.8% | Unchanged | 9,100 | $370K |
| Pacira Biosciences Inc | 1.6% | Unchanged | 13,500 | $342K |
| Regenxbio Inc | 1.5% | Unchanged | 26,600 | $319K |
| Rocket Pharmaceuticals Inc | 1.4% | Unchanged | 86,000 | $294K |
| Janux Therapeutics Inc | 1.4% | Unchanged | 19,000 | $292K |
| Mineralys Therapeutics Inc | 1.4% | Unchanged | 10,500 | $283K |
| Gh Research PLC | 1.3% | Unchanged | 10,200 | $274K |
| Seres Therapeutics Inc | 1.2% | Unchanged | 31,570 | $249K |
| Azenta Inc | 1.2% | Unchanged | 9,700 | $248K |
| Jasper Therapeutics Inc | 0.9% | Unchanged | 465,000 | $196K |
| Innoviva Inc | 0.9% | Unchanged | 8,200 | $186K |
| IP Innate Pharma S A | 0.7% | Unchanged | 81,151 | $149K |
| Arcutis Biotherapeutics Inc | 0.7% | Unchanged | 5,250 | $138K |
| Spruce Biosciences Inc | 0.3% | Unchanged | 1,000 | $54K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cue Biopharma Inc | New | +52,928 | +$1.67M | 8.0% |
| Cue Biopharma Inc | Exited | −2,202,854 | −$506K | — |
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| DO Day One Biopharmaceuticals I | Exited | −42,000 | −$391K | — |
| Ventyx Biosciences Inc | Exited | −41,500 | −$375K | — |
| Minerva Neurosciences Inc | Exited | −35,000 | −$141K | — |
| Compass Pathways PLC | Added | +22,000 | +$122K | 2.6% |
| Humacyte Inc | Added | +150,000 | +$91K | 2.4% |
| MP Milestone Pharmaceuticals In | Added | +65,000 | +$77.4K | 5.8% |
| Mersana Therapeutics Inc | Exited | −100 | −$2.89K | — |
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Mineralys Therapeutics Inc | Trimmed | −28,500 | −$1.03M | 2.0% |
| Avadel Pharmaceuticals PLC | Exited | −59,700 | −$912K | — |
| KP Kiniksa Pharmaceuticals Intl | Exited | −23,400 | −$909K | — |
| Insmed Inc | Exited | −6,250 | −$900K | — |
| Arcutis Biotherapeutics Inc | Trimmed | −30,050 | −$873K | 0.8% |
| Mersana Therapeutics Inc | Trimmed | −25,660 | −$742K | — |
| Cue Biopharma Inc | New | +2,202,854 | +$673K | 3.5% |
| Bridgebio Pharma Inc | Trimmed | −8,300 | −$635K | 2.0% |
| Sarepta Therapeutics Inc | New | +28,500 | +$613K | 3.2% |
| Regenxbio Inc | Trimmed | −31,150 | −$449K | 2.0% |
Showing the 10 largest of 34 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Mineralys Therapeutics Inc | Trimmed | −40,000 | −$1.52M | 8.4% |
| Ardelyx Inc | Trimmed | −172,650 | −$951K | 5.1% |
| KP Kiniksa Pharmaceuticals Intl | Trimmed | −22,500 | −$874K | 5.2% |
| Royalty Pharma PLC | New | +21,400 | +$755K | 4.3% |
| Fennec Pharmaceuticals Inc | Trimmed | −72,700 | −$680K | 6.5% |
| Bridgebio Pharma Inc | Trimmed | −12,700 | −$660K | 3.9% |
| Insmed Inc | Trimmed | −4,400 | −$634K | 5.1% |
| Jasper Therapeutics Inc | Added | +252,058 | +$600K | 5.4% |
| Avadel Pharmaceuticals PLC | Trimmed | −39,000 | −$596K | 5.2% |
| Moonlake Immunotherapeutics | New | +67,500 | +$484K | 2.7% |
Showing the 10 largest of 21 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Insmed Inc | Trimmed | −19,850 | −$2M | 7.3% |
| Bluebird Bio Inc | Exited | −78,912 | −$385K | — |
| Seres Therapeutics Inc | Exited | −340,761 | −$239K | — |
| Seres Therapeutics Inc | New | +17,038 | +$189K | 1.3% |
| Spruce Biosciences Inc | Exited | −75,000 | −$21.8K | — |
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bridgebio Pharma Inc | Trimmed | −14,300 | −$494K | 5.7% |
| Jasper Therapeutics Inc | Added | +114,500 | +$492K | 4.0% |
| Insmed Inc | Trimmed | −6,200 | −$473K | 14.8% |
| MP Milestone Pharmaceuticals In | Trimmed | −477,000 | −$382K | 2.8% |
| Avadel Pharmaceuticals PLC | Added | +34,700 | +$272K | 4.9% |
| Mersana Therapeutics Inc | New | +644,000 | +$222K | 1.4% |
| Humacyte Inc | New | +83,500 | +$142K | 0.9% |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IT Ishares Tr | Exited | −82,500 | −$18.2M | — |
| Mirum Pharmaceuticals Inc | Exited | −45,000 | −$1.76M | — |
| MP Milestone Pharmaceuticals In | Trimmed | −628,348 | −$1.48M | 12.7% |
| Marinus Pharmaceuticals Inc | Exited | −693,778 | −$1.22M | — |
| Insmed Inc | Trimmed | −15,500 | −$1.07M | 13.3% |
| Bluebird Bio Inc | Exited | −1,578,256 | −$820K | — |
| Bluebird Bio Inc | New | +78,912 | +$658K | 3.4% |
| Biohaven Ltd | Trimmed | −12,700 | −$474K | 4.4% |
| Geron Corp | Trimmed | −130,000 | −$460K | 9.3% |
| KP Kiniksa Pharmaceuticals Ltd | Trimmed | −15,500 | −$307K | 4.8% |
Showing the 10 largest of 20 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Ser Tr | Exited | −50,000 | −$4.64M | — |
| Ardelyx Inc | Trimmed | −486,667 | −$3.35M | 5.7% |
| Marinus Pharmaceuticals Inc | Trimmed | −1,421,049 | −$2.5M | 2.7% |
| Biohaven Ltd | New | +35,400 | +$1.77M | 3.9% |
| Insmed Inc | Trimmed | −18,135 | −$1.32M | 8.5% |
| Neurocrine Biosciences Inc | Exited | −8,350 | −$1.15M | — |
| KP Kiniksa Pharmaceuticals Ltd | Trimmed | −43,291 | −$1.08M | 3.4% |
| MP Milestone Pharmaceuticals In | Trimmed | −686,053 | −$1.04M | 5.6% |
| Enphys Acquisition Corp | Exited | −78,125 | −$858K | — |
| Burgerfi International Inc | Exited | −2,745,938 | −$557K | — |
Showing the 10 largest of 21 changes.
Loading...
